CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

NCT04626765 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG: CD19 CAR-T
DRUG: CD22 CAR-T
DRUG: CD 19+22
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Collaborators

[object Object]